Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05367440 · ClinicalTrials.gov registry record · Phase 1

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

A Phase 1 study of Metastatic Prostate Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
174
Enrollment target
20
Study locations

NCT05367440: Active Phase 1 study of Metastatic Prostate Cancer, sponsored by AstraZeneca.

NCT05367440 is a Phase 1 study of Metastatic Prostate Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 174 participants, roughly in line with the 182-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target. The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05367440, a Phase 1 study of Metastatic Prostate Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
174 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.

Primary Outcome

Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline will be assessed.

Conditions Studied

Metastatic Prostate Cancer

Interventions

  • DRUG Darolutamide
  • DRUG Apalutamide
  • DRUG Enzalutamide
  • DRUG Abiraterone Acetate
  • DRUG AZD5305

Study Locations (20)

Other

  • Research Site - Camperdown
  • Research Site - Darlinghurst
  • Research Site - East Melbourne
  • Research Site - Heidelberg
  • Research Site - Melbourne
  • Research Site - St Leonards
  • Research Site - Candiolo
  • Research Site - Milan
  • Research Site - Orbassano
  • Research Site - Padua
  • Research Site - Cambridge
  • Research Site - Glasgow
  • Research Site - Manchester
  • Research Site - Plymouth

Michigan

  • Research Site - Detroit
  • Research Site - Detroit

Texas

  • Research Site - Houston
  • Research Site - Houston

New York

  • Research Site - Syracuse

South Carolina

  • Research Site - Myrtle Beach

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2022-06-02
Est. Completion 2031-04-11
Phase Phase 1
AstraZeneca

1,285 total trials

What the registry record for NCT05367440 still lists

NCT05367440 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 182-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target.

The record links to 1 condition, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Darolutamide is the first listed.

NCT05367440 names 20 study sites across 5 states, led by Other, Michigan, Texas.

Frequently Asked Questions

What is clinical trial NCT05367440 about?

NCT05367440 is a clinical study titled "Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer". This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.

What is the current status of trial NCT05367440?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2022-06-02. Estimated completion is 2031-04-11.

What conditions does trial NCT05367440 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer.

What interventions are being tested in trial NCT05367440?

The interventions under investigation include: Darolutamide (DRUG), Apalutamide (DRUG), Enzalutamide (DRUG), Abiraterone Acetate (DRUG), AZD5305 (DRUG).

Who is sponsoring clinical trial NCT05367440?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05367440 being conducted?

This trial has 20 study locations across Michigan, New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05367440's enrollment target sits among peer trials

174 13th of 41 higher than 29 of 41 other Metastatic Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01000259 · 174 participants

    Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

  • NCT04729114 · 174 participants · Phase 1

    A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

  • NCT04884035 · 174 participants · Phase 1

    Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

  • NCT05075980 · 174 participants · Phase 2

    Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05367440, the US trial registry maintained by the National Library of Medicine. NCT05367440 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.